Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

被引：10
|
作者：
Goldenberg, Ronald M. [1 ]
Verma, Subodh [2 ]
Perkins, Bruce A. [3 ]
Gilbert, Jeremy D. [4 ]
Zinman, Bernard [5 ]
机构：
[1] LMC Diabet & Endocrinol, Thornhill, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Surg,Div Cardiac Surg, Toronto, ON, Canada
[3] Univ Toronto, Mt Sinai Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Div Endocrinol & Metab, Toronto, ON, Canada
[5] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 01期
关键词：
TYPE-2; DIABETES-MELLITUS; PANCREATIC ALPHA-CELLS; DAPAGLIFLOZIN ADD-ON; DOUBLE-BLIND; POSTPRANDIAL GLUCAGON; BETA-CELLS; METFORMIN; THERAPY; SAXAGLIPTIN; SECRETION;
D O I：
10.1016/j.jcjd.2016.08.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 9
页数：4
相关论文
共 50 条
  • [21] Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study
    Sergio Gamaza-Chulián
    Enrique Díaz-Retamino
    Fátima González-Testón
    José Carlos Gaitero
    María José Castillo
    Raquel Alfaro
    Elías Rodríguez
    Eva González-Caballero
    Antonio Martín-Santana
    BMC Cardiovascular Disorders, 21
  • [22] Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
    Ruanpeng, Darin
    Ungprasert, Patompong
    Sangtian, Jutarat
    Harindhanavudhi, Tasma
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (06)
  • [23] Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention
    Reid, Jessica
    Rana, Khyatiben
    Niman, Stephanie
    Sheikh-Ali, Mae
    Lewis, Todd
    Choksi, Rushab R.
    Goldfaden, Rebecca F.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 419 - 429
  • [24] Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
    da Silva, Paula Nogueira
    da Conceicao, Raissa Alves
    Maia, Rodolfo do Couto
    de Castro Barbosa, Maria Leticia
    MEDCHEMCOMM, 2018, 9 (08) : 1273 - 1281
  • [25] Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science
    Cruz, Joseph E.
    Ahuja, Tania
    Bridgeman, Mary Barna
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1238 - 1249
  • [26] Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
    Kramer, Caroline K.
    Zinman, Bernard
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 323 - 334
  • [27] Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
    Li, Hang-Long
    Lip, Gregory-Y H.
    Feng, Qi
    Fei, Yue
    Tse, Yi-Kei
    Wu, Mei-Zhen
    Ren, Qing-Wen
    Tse, Hung-Fat
    Cheung, Bernard-M Y.
    Yiu, Kai-Hang
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [28] Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i)
    Alqudsi, Muhannad
    Velez, Juan Carlos Q.
    Navarrete, Jose
    CURRENT OPINION IN CARDIOLOGY, 2021, 36 (04) : 420 - 428
  • [29] Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
    Lim, Soo
    Eckel, Robert H.
    Koh, Kwang Kon
    ATHEROSCLEROSIS, 2018, 272 : 33 - 40
  • [30] Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
    Li, Hang-Long
    Tse, Yi-Kei
    Chandramouli, Chanchal
    Hon, Nicole Wing-Lam
    Cheung, Ching-Lung
    Lam, Lok-Yee
    Wu, Meizhen
    Huang, Jia-Yi
    Yu, Si-Yeung
    Leung, Ka-Lam
    Fei, Yue
    Feng, Qi
    Ren, Qingwen
    Cheung, Bernard M. Y.
    Tse, Hung-Fat
    Verma, Subodh
    Lam, Carolyn S. P.
    Yiu, Kai-Hang
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (12): : 3442 - 3451
12345